Goldman Sachs Group Inc Theseus Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

$555 Billion
Q1 2024

A detailed history of Goldman Sachs Group Inc transactions in Theseus Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 30,366 shares of THRX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,366

Previous 16,982 78.81%

Holding current value

Previous $68,000 100.0%

% of portfolio

0.0%

Previous 0.0%

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.0 - $4.08 $0 - $54,606	13,384 Added 78.81%	30,366 $0
Q4 2023 Feb 13, 2024	BUY	$2.12 - $4.18 $36,001 - $70,984	16,982 New	16,982 $68,000
Q2 2023 May 14, 2024	BUY	$7.28 - $11.82 $87,061 - $141,355	11,959 Added 70.42%	28,941 $270,000
Q2 2023 Aug 14, 2023	BUY	$7.28 - $11.82 $210,690 - $342,082	28,941 New	28,941 $270,000

Others Institutions Holding THRX

# of Institutions

Shares Held

1.06M

Call Options Held

Put Options Held

View Full List

About Theseus Pharmaceuticals, Inc.

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

More about THRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Theseus Pharmaceuticals, Inc. Transaction History